Brokerages Expect Viveve Medical Inc (VIVE) Will Announce Quarterly Sales of $5.30 Million

Share on StockTwits

Equities research analysts expect Viveve Medical Inc (NASDAQ:VIVE) to report sales of $5.30 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Viveve Medical’s earnings. The highest sales estimate is $5.70 million and the lowest is $4.37 million. Viveve Medical posted sales of $4.07 million in the same quarter last year, which suggests a positive year over year growth rate of 30.2%. The firm is expected to issue its next earnings report on Wednesday, November 14th.

According to Zacks, analysts expect that Viveve Medical will report full-year sales of $21.21 million for the current year, with estimates ranging from $20.14 million to $21.90 million. For the next financial year, analysts expect that the business will report sales of $32.84 million per share, with estimates ranging from $29.12 million to $34.91 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Viveve Medical.

Viveve Medical (NASDAQ:VIVE) last announced its quarterly earnings results on Thursday, August 9th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.01. The company had revenue of $5.53 million during the quarter, compared to analysts’ expectations of $4.97 million. Viveve Medical had a negative return on equity of 568.79% and a negative net margin of 239.33%.

A number of analysts have recently commented on the company. ValuEngine raised Viveve Medical from a “hold” rating to a “buy” rating in a research note on Monday, July 2nd. Craig Hallum cut Viveve Medical from a “buy” rating to a “hold” rating in a research note on Friday, May 11th. Finally, Stifel Nicolaus assumed coverage on Viveve Medical in a research note on Tuesday, April 17th. They issued a “buy” rating and a $6.00 price target for the company. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $9.20.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN increased its stake in Viveve Medical by 135.1% during the 4th quarter. Wells Fargo & Company MN now owns 37,727 shares of the company’s stock worth $188,000 after purchasing an additional 21,683 shares in the last quarter. LMR Partners LLP bought a new stake in Viveve Medical during the 2nd quarter worth approximately $112,000. Spark Investment Management LLC bought a new stake in Viveve Medical during the 1st quarter worth approximately $208,000. BlackRock Inc. increased its stake in Viveve Medical by 8.1% during the 1st quarter. BlackRock Inc. now owns 780,591 shares of the company’s stock worth $2,857,000 after purchasing an additional 58,256 shares in the last quarter. Finally, Northern Trust Corp increased its stake in Viveve Medical by 43.4% during the 1st quarter. Northern Trust Corp now owns 252,974 shares of the company’s stock worth $926,000 after purchasing an additional 76,519 shares in the last quarter. 67.35% of the stock is owned by institutional investors and hedge funds.

Shares of VIVE stock traded up $0.13 on Thursday, reaching $2.60. The company had a trading volume of 236,717 shares, compared to its average volume of 202,292. The company has a quick ratio of 6.00, a current ratio of 6.47 and a debt-to-equity ratio of 1.55. Viveve Medical has a 12 month low of $1.60 and a 12 month high of $7.25.

Viveve Medical Company Profile

Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories.

Read More: Understanding Average Daily Trade Volume

Get a free copy of the Zacks research report on Viveve Medical (VIVE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply